S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$520.17
+1.89 (+0.36 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$507.34
Now: $520.17
$526.37
50-Day Range
$465.18
MA: $507.68
$551.79
52-Week Range
$168.65
Now: $520.17
$573.99
Volume593,900 shs
Average Volume470,700 shs
Market Capitalization$44.44 billion
P/E Ratio90.62
Dividend YieldN/A
Beta0.88
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IDEXX Laboratories logo

Headlines

Love Your Pets? Buy and Hold This Growth Stock for Life, Too
February 19, 2021 |  finance.yahoo.com
IDEXX Laboratories: An Impressive Earnings Growth Story
February 3, 2021 |  seekingalpha.com
Nasdaq 100 Movers: MRNA, IDXX
February 2, 2021 |  marketwatch.com
IDEXX Laboratories Inc Q4 Income Rises
February 2, 2021 |  nasdaq.com
IDEXX Laboratories, Inc. to Host Earnings Call
February 2, 2021 |  finance.yahoo.com
Earnings Preview for IDEXX Laboratories
February 1, 2021 |  benzinga.com
Could IDEXX Laboratories (NASDAQ:IDXX) Multiply In Value?
January 29, 2021 |  finance.yahoo.com
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3
January 28, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300
Employees9,000
Year Founded1983

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$6.29 per share
Book Value$2.07 per share

Profitability

Net Income$427.72 million

Miscellaneous

Market Cap$44.44 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

503rd out of 1,962 stocks

Diagnostic Substances Industry

10th out of 32 stocks

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$520.17
+1.89 (+0.36 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

Is IDEXX Laboratories a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its earnings results on Tuesday, February, 2nd. The company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.62. The company had revenue of $720.90 million for the quarter, compared to the consensus estimate of $680.03 million. IDEXX Laboratories had a net margin of 19.20% and a trailing twelve-month return on equity of 198.91%. The firm's revenue for the quarter was up 19.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.04 earnings per share.
View IDEXX Laboratories' earnings history
.

How has IDEXX Laboratories' stock been impacted by COVID-19?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IDXX stock has increased by 111.8% and is now trading at $520.17.
View which stocks have been most impacted by COVID-19
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its Board of Directors has authorized a share buyback plan on Wednesday, February 12th 2020, which authorizes the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its stock is undervalued.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY21 earnings guidance on Tuesday, February, 2nd. The company provided earnings per share (EPS) guidance of $7.39-7.71 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.79. The company issued revenue guidance of $3.065-3.120 billion, compared to the consensus revenue estimate of $2.95 billion.

What price target have analysts set for IDXX?

5 brokerages have issued 12 month target prices for IDEXX Laboratories' shares. Their forecasts range from $375.00 to $600.00. On average, they anticipate IDEXX Laboratories' stock price to reach $471.40 in the next year. This suggests that the stock has a possible downside of 9.4%.
View analysts' price targets for IDEXX Laboratories
or view top-rated stocks among Wall Street analysts.

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan J. Mazelsky, Pres, CEO & Director (Age 60, Pay $1.62M)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 59, Pay $1.14M)
  • Ms. Sharon E. Underberg, Sr. VP, Gen. Counsel & Corp. Sec. (Age 60, Pay $809.42k)
  • Ms. Kathy V. Turner, Chief Marketing Officer & Sr. VP (Age 56, Pay $1.95M)
  • Mr. Jonathan W. Ayers, Sr. Advisor & Director (Age 65, Pay $3.2M)
  • Mr. Michael J. Lane, Exec. VP and GM of Reference Laboratories & Information Technology (Age 53, Pay $724.02k)
  • Mr. John Hart, Sr. VP of Worldwide Operations
  • Mr. Jeffery D. Chadbourne, Sr. Director of Accounting & Financial Reporting (Age 45)
  • Mr. Jeffrey Thomas, Sr. VP & Chief Technology Officer
  • Mr. Ken Grady, Sr. VP & Chief Information Officer

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.25%), Fundsmith LLP (4.95%), Bamco Inc. NY (3.64%), Price T Rowe Associates Inc. MD (2.36%), Blair William & Co. IL (1.73%) and Alliancebernstein L.P. (1.63%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jay Mazelsky, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Bamco Inc. NY, Wells Fargo & Company MN, Lazard Asset Management LLC, Baird Financial Group Inc., Principal Financial Group Inc., Squarepoint Ops LLC, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson, and Sophie V Vandebroek.
View insider buying and selling activity for IDEXX Laboratories
or view top insider-selling stocks.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank Julius Baer & Co. Ltd Zurich, Manning & Napier Group LLC, Lord Abbett & CO. LLC, BlackRock Inc., Brown Advisory Inc., Nuveen Asset Management LLC, and WCM Investment Management LLC.
View insider buying and selling activity for IDEXX Laboratories
or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $520.17.

How much money does IDEXX Laboratories make?

IDEXX Laboratories has a market capitalization of $44.44 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

IDEXX Laboratories employs 9,000 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

Where are IDEXX Laboratories' headquarters?

IDEXX Laboratories is headquartered at ONE IDEXX DRIVE, WESTBROOK ME, 04092.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.